진단용 피부과 기기 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the diagnostic dermatology equipment market size is expected to increase from USD 8.70 billion in 2025 to USD 9.45 billion in 2026 and reach USD 14.30 billion by 2031, growing at a CAGR of 8.66% over 2026-2031.

This report is Segmented by Device (Dermatoscopes, and More), Portability (Handheld/Pocket Dermatoscopes, Stationary/Fixed Dermatoscope, and More), Application (Skin Cancer, and More), End-User (Hospitals, Dermatology Clinics & Centers, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Diagnostic Dermatology Equipment Market Trends and Insights

Rising Skin Cancer Incidence and Screening Program Expansion

Skin cancer prevalence keeps early detection at the center of care delivery, which prompts sustained investment in diagnostic imaging. In the United States, in 2025, an estimated 104,960 new cases of invasive melanoma and localized melanoma carry a 99% five-year survival rate, which motivates system-level screening initiatives and image-guided triage pathways that can be scaled into primary care settings. Australia continues to face one of the world's highest melanoma incidence rates, and national stakeholders maintain a strong emphasis on targeted screening and enhanced access to diagnostic tools for timely intervention. This clinical reality supports steady demand for connected dermatoscopes and interoperable imaging platforms that enable store-and-forward consultations and streamline referrals to dermatology. Health agencies and professional associations also promote prevention and screening activities, which indirectly sustain device utilization across the diagnostic dermatology equipment market. As health systems standardize protocols, the Diagnostics dermatology equipment market tracks consistent upgrades from standalone optical tools to integrated image-management and AI-supported review.

Shift to Non-Invasive Imaging

Non-invasive imaging is expanding clinical use because it helps stratify lesions before biopsy and supports treatment decisions with high-resolution structural information. LC-OCT and OCT platforms demonstrate strong clinical performance and operating efficiency, with LC-OCT providing near-cellular resolution and deeper penetration to visualize epidermal and dermal architecture in one session. The FDA clearance of an LC-OCT system in March 2025 formalized U.S. entry for this hybrid modality, which strengthens clinician confidence in optical workflows that can reduce unnecessary excisions and guide pre-surgical margin assessment. Correlation studies continue to show high agreement with histopathology for key basal cell carcinoma features, which helps embed OCT and LC-OCT in diagnostic pathways before invasive sampling. As non-invasive imaging aligns with faster clinical decisions, the Diagnostics dermatology equipment market benefits from replacement cycles that prioritize higher-resolution devices and interoperable software. AI-Enabled Diagnostic Tools and Teledermatology Adoption

High Acquisition and Ownership Costs for Advanced Systems

Capital intensity remains a constraint, especially for private practices and smaller clinics that face tight operating margins. Advanced imaging suites and total-body 3D systems require facility readiness, trained staff, and IT infrastructure for secure storage, which compounds initial outlays beyond device price. Integration with clinical photography and AI software also involves ongoing licensing and upgrades, which commits providers to recurring expenses over multi-year periods. These realities encourage phased adoption that starts with connected dermatoscopes and image-management software, then proceeds to non-invasive imaging modules as case volumes grow. Where hospital systems lead capital programs, deployments cluster in academic centers with research and training mandates, while community facilities progress through shared-service models and teledermatology alliances. This staged approach moderates near-term purchasing, yet it preserves demand for interoperable platforms in the diagnostics dermatology equipment market.

Other drivers and restraints analyzed in the detailed report include:

1. RCM Reimbursement Momentum (Category-1 CPT Codes)
2. Emergent LC-OCT Hybrid Modality Expands Use-Cases
3. Shortage of Trained Operators; Workflow Time Constraints

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Dermatoscopes commanded 32.10% share of the diagnostics dermatology equipment market size in 2025, affirming their position as the entry point for triage across primary care and dermatology. Routine use of connected dermatoscopes helps standardize image capture and supports store-and-forward workflows, which expands access for patients and accelerates referrals to specialists when needed. OCT platforms are projected to post the highest growth at an 8.90% CAGR during 2026-2031, driven by use cases that include lesion stratification and treatment planning for superficial versus non-superficial basal cell carcinoma. Clinical correlation continues to validate hybrid LC-OCT for BCC features that align with histopathology, which strengthens clinician trust in non-invasive imaging as a pre-biopsy step. As software becomes the organizing layer for image management and remote review, the diagnostics dermatology equipment market tilts toward integrated ecosystems that combine optical capture, AI decision support, and archival.

Handheld or pocket dermatoscopes held a 36.10% share in 2025 and are projected to grow at an 8.60% CAGR through 2031, reflecting their role at the front line of skin lesion evaluation and remote triage. Smartphone-compatible accessories and connected workflows improve image quality consistency and enable primary-care users to refer higher-risk cases efficiently. Stationary dermatoscopes and fixed optical systems remain critical in high-volume clinics, where stable optics and integrated capture rigs reduce motion artifacts and support standardized examinations. Trolley-mounted imaging suites that automate body mapping accelerate longitudinal monitoring and data capture, especially when paired with AI-enabled change detection. These device formats expand the diagnostics dermatology equipment market by covering both quick capture in primary care and more comprehensive imaging in specialty centers. Benchtop or console systems for RCM and OCT anchor specialist workflows that need near-histologic detail or deeper structural views to guide management. Hospitals and academic centers typically deploy these systems to help teams maintain technique, interpretation skills, and standardized reporting. The diagnostics dermatology equipment market increasingly favors interoperable software for image archiving, annotations, and remote reads, which reduces friction across multi-site networks. Portfolio breadth across handheld, stationary, and console formats strengthens vendor positioning as providers align purchases with diverse clinical use cases across the care continuum.

Geography Analysis

North America accounted for 39.60% share of the diagnostics dermatology equipment market size in 2025, supported by defined reimbursement frameworks for confocal imaging and institutional investment in non-invasive diagnostics. Medicare has maintained CPT pathways for RCM with specified national payment amounts, which anchor billing and pave the way for broader clinical use in select centers. Rising emphasis on skin cancer prevention and early detection also reinforces consistent device utilization across screening and oncology programs. The FDA's AI and machine learning framework for medical devices introduces a predictable route for algorithm updates, which shortens innovation cycles for AI-enabled imaging solutions in the diagnostics and dermatology equipment market.

Europe maintains significant adoption across Germany, France, and the United Kingdom, where robust clinical infrastructure and public coverage support advanced imaging. EU-centered innovation in LC-OCT has accelerated with recent United States FDA clearance, which encourages transatlantic clinical validation and best-practice exchange. Provider networks emphasize quality and compliance, which favors imaging platforms with clear clinical evidence and defined postmarket plans. As hospital systems scale longitudinal monitoring and integrate AI-assisted change analysis, use cases broaden beyond oncology toward inflammatory dermatoses characterization. This environment supports continued platform adoption that integrates dermoscopy, OCT, and LC-OCT into unified workflows in the diagnostics dermatology equipment market.

Asia Pacific is the fastest-growing region with an 8.90% projected CAGR during 2026-2031, led by the continued expansion of dermatology services and the diffusion of teledermatology in underserved areas. Australia illustrates the region's high-risk profile, with age-standardized incidence among the highest worldwide and a sustained national focus on targeted screening and rural access to imaging. As health systems promote remote care and standardized screening, handheld dermatoscopes gain traction in community settings supported by image-management software and remote reading. Company-led initiatives to extend 3D body-mapping access in communities outside major metro areas further underline the role of mobile imaging in APAC's growth trajectory. These developments expand the diagnostic dermatology equipment market by connecting primary care to specialist centers through interoperable imaging and AI triage workflows.

1. Canfield Scientific
2. Cortex Technology (DermaLab)
3. Damae Medical (deepLive LC-OCT)
4. DermaSensor Inc.
5. DermLite
6. DermoScan GmbH
7. FotoFinder Systems
8. HEINE Optotechnik
9. ILLUCO Corpo
10. Kirchner & Wilhelm GmbH + Co. KG
11. MedX Health Corp.
12. MetaOptima Technology (DermEngine)
13. Michelson Diagnostics Ltd. (VivoSight)
14. Optilia Instruments
15. SciBase
16. VivaScope GmbH

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Skin Cancer Incidence and Screening Program Expansion
  • 4.2.2 Shift to Non-Invasive Imaging
  • 4.2.3 AI-Enabled Diagnostic Tools and Teledermatology Adoption
  • 4.2.4 RCM Reimbursement Momentum (Category-1 CPT Codes)
  • 4.2.5 Emergent LC-OCT Hybrid Modality Expands Use-Cases
• 4.3 Market Restraints
  • 4.3.1 High Acquisition and Ownership Costs for Advanced Systems
  • 4.3.2 Shortage of Trained Operators; Workflow Time Constraints
  • 4.3.3 Regulatory/Data-Governance Hurdles for AI/ML (Samd)
  • 4.3.4 Inconsistent Reimbursement for Imaging/Teledermatology
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Device
  • 5.1.1 Dermatoscopes
  • 5.1.2 Digital Photographic Imaging Systems
  • 5.1.3 Reflectance Confocal Microscopy (RCM)
  • 5.1.4 Optical Coherence Tomography (OCT)
  • 5.1.5 High-Frequency Ultrasound (HFUS)
  • 5.1.6 Electrical Impedance Spectroscopy (EIS)
  • 5.1.7 Total Body 3D Imaging Systems
  • 5.1.8 Microscopes And Trichoscopes
  • 5.1.9 Skin Biopsy Diagnostics Instruments
  • 5.1.10 Others
• 5.2 By Portability
  • 5.2.1 Handheld/Pocket Dermatoscopes
  • 5.2.2 Stationary/Fixed Dermatoscope
  • 5.2.3 Trolley-Mounted/Tabletop Imaging Systems
  • 5.2.4 Benchtop/Console RCM And OCT Systems
  • 5.2.5 Others
• 5.3 By Application
  • 5.3.1 Skin Cancer Diagnosis
    • 5.3.1.1 Melanoma
    • 5.3.1.2 Non-melanoma Skin Cancers
  • 5.3.2 Pigmented Lesion Mapping & Longitudinal Monitoring
  • 5.3.3 Inflammatory Skin Diseases
  • 5.3.4 Hair & Scalp Disorders
  • 5.3.5 Aesthetic & Dermatologic Surgery Planning/Documentation
  • 5.3.6 Other Applications
• 5.4 By End-User
  • 5.4.1 Hospitals
  • 5.4.2 Dermatology Clinics & Centers
  • 5.4.3 Primary Care & Ambulatory Care Centers
  • 5.4.4 Academic & Research Institutes
  • 5.4.5 Others
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level Overview, Core Segments, Financials as Available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 Canfield Scientific, Inc.
  • 6.3.2 Cortex Technology (DermaLab)
  • 6.3.3 Damae Medical (deepLive LC-OCT)
  • 6.3.4 DermaSensor Inc.
  • 6.3.5 DermLite
  • 6.3.6 DermoScan GmbH
  • 6.3.7 FotoFinder Systems GmbH
  • 6.3.8 HEINE Optotechnik GmbH & Co. KG
  • 6.3.9 ILLUCO Corporation Ltd.
  • 6.3.10 Kirchner & Wilhelm GmbH + Co. KG
  • 6.3.11 MedX Health Corp.
  • 6.3.12 MetaOptima Technology (DermEngine)
  • 6.3.13 Michelson Diagnostics Ltd. (VivoSight)
  • 6.3.14 Optilia Instruments AB
  • 6.3.15 SciBase
  • 6.3.16 VivaScope GmbH

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment